Adjuvant Therapy on the Clinical Outcome of Patients With Desmoid Tumors After, Surgical Resection, The Aim of the Study is to Evaluate the Efficacy of Photodynamic Therapy as an
Conditions
Brief summary
The purpose of this study is to evaluate the efficacy of preoperative 5-ALA oral administration and subsequently intraoperative tumor bed phototherapy with red light laser, as an adjuvant therapy on the 3 years rate of local tumor recurrence in patients with desmoid tumors. To evaluate the Safety of 5-ALA administration. 5 years local recurrence rate.
Interventions
DRUG5-AMINOLEVULINIC ACID (5-ALA), is a non fluorescent prodrug.
60 mg/kg 5-ALA prepared solution given orally, 3-5 hours before induction of anesthesia. Red light laser given by a Dye laser system, wave length of 635nm, in s dose of 150J/cm for 2000 seconds (33 minutes) will be given to tumor bed. In case of positive margins a second operation and 5-ALA administration or irradiation will be given.
Sponsors
michal roll
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient has a resectable histologically confirmed desmoid tumor. 2. Previously treated (by chemotherapy, irradiation or surgery) patients are eligible. 3. Age \> 18 years 4. Signed informed consent prior to patient recruitment. -
Exclusion criteria
1. Hepatic enzymes or bilirubin \> 2X upper limit of normal. 2. Serum creatinine \> 2.5 x upper limit of normal. 3. Suspected /documented metastatic disease. 4. Active or uncontrolled infections. 5. Active second malignant disease (excluding non-melanoma skin cancer, or in situ cervix or breast carcinoma) \< 2 years prior to the study. 6. Use of other investigational agents \< 30 days prior to the study. 7. Patients who are mentally or physically unable to comply with all aspects of the study. 8. Any serious medical condition, including the presence of laboratory abnormalities, which places the subject at an unacceptable risk if he or she participates in this study or confounds the experimental ability to interpret data from the study. 9. Pregnant or lactating females. 10. Known intolerance or allergy to 5-ALA 11. Suspicious or documented acute or chronic porphyria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is a binary variable where each patient is classified as a recurrence or a not recurrence case and will be determined by calculating the proportion of recurrence versus non recurrence rates | three years |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To assess the safety of study drug administration in the study population. To assess the 5 years local recurrence rate. | five years | Data from all subjects who receive any study drug will be included in the safety analyses. The severity of the toxicities will be graded according to the NCI CTCAE whenever possible. Adverse events will be summarized by worst NCI CTC grade. Adverse events classified as NCI CTCAE Grade 3 or Grade 4, study-drug-related events, and serious adverse events will be summarized separately. Laboratory data will be graded according to NCI CTCAE severity grade. |
Countries
Israel
Contacts
Primary ContactJacob Bickels, MD/PhD
Outcome results
None listed